Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells 35,000 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 35,000 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares in the company, valued at $48,259,497. This trade represents a 3.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Supernus Pharmaceuticals Trading Up 0.6%

Shares of SUPN traded up $0.30 during trading hours on Monday, reaching $50.21. 517,222 shares of the stock traded hands, compared to its average volume of 762,366. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -73.84, a PEG ratio of 1.55 and a beta of 0.70. The stock has a fifty day simple moving average of $51.22 and a 200 day simple moving average of $49.10. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68.

Analysts Set New Price Targets

SUPN has been the topic of a number of research reports. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus upped their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $62.17.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $21,908,000. Woodline Partners LP raised its position in shares of Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares during the period. Bank of America Corp DE increased its position in shares of Supernus Pharmaceuticals by 67.1% during the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after purchasing an additional 338,584 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Supernus Pharmaceuticals by 42.9% in the 4th quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock worth $53,650,000 after acquiring an additional 324,154 shares during the last quarter. Finally, UBS Group AG lifted its stake in Supernus Pharmaceuticals by 137.6% during the third quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock worth $25,812,000 after purchasing an additional 312,775 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.